Your email has been successfully added to our mailing list.

×
0.00537634408602139 0.00537634408602139 -0.00537634408602158 -0.00537634408602158 -0.00537634408602158 -0.00537634408602158 0.0430107526881721 0.0225806451612902
Stock impact report

Virpax Pharmaceuticals CEO and Chairman Anthony Mack Resigns [MarketWatch]

Silence Therapeutics Plc - American Depository Share (SLN) 
Company Research Source: MarketWatch
Mack will be succeeded by Gerald Bruce as CEO and Eric Floyd as chairman. Bruce has been executive vice president of commercial operations at Virpax since 2017, while Floyd is senior vice president of regulatory affairs and quality assurance at London-based pharmaceutical company Silence Therapeutics. Advertisement "It has been an honor to lead a team of such dedicated and talented colleagues," Mack said. Virpax Pharmaceuticals is working on developing non-addictive pain-management products as well as other products. Write to Will Feuer at Will.Feuer@wsj.com Show less Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SLN alerts

from News Quantified
Opt-in for
SLN alerts

from News Quantified